Background {#s1}
==========

Medullary thyroid carcinoma (MTC), originating from parafollicular C-cells, accounts for 5% of all thyroid cancers and can occur as sporadic (75% of cases) or hereditary (25%) disease ([@B1]). Germline *RET* proto-oncogene variants play a crucial pathogenetic role and are found in the majority of hereditary forms (98%). In fact, only few families with hereditary MTC do not show any germline variant ([@B2]). On the other hand, somatic *RET* variants are responsible for approximately 40% of cases of sporadic MTC, according to data of COSMIC database published in 2015 ([@B3]). The *RET* proto-oncogene, located on chromosome 10, codifies for a member of the tyrosine-kinase family receptors which is expressed on C cells, parathyroid glands, adrenal medulla and urogenital tract. In the hereditary forms, the causative role of the germline *RET* variants has been clearly demonstrated, and there appears to be a strict correlation between genotype and phenotype, leading to different degree of risk related to the aggressiveness of the tumor and the clinical syndrome \[familiar medullary thyroid cancer (FMTC), and type 2A and type 2B multiple endocrine neoplasia (MEN) ([@B4])\]. The "classic MEN2A" phenotype is characterized by the concomitant occurrence of pheochromocytoma and primary hyperparathyroidism. In addition to the "classic MEN2A," other forms associated with cutaneous lichen amyloidosis ([@B5]) and with Hirschsprung disease have been reported ([@B6]). MEN2A is primarily associated with variants in the *RET* gene causing substitution of cysteines at codons 609, 611, 618, and 620 in exon 10, and particularly with the Cys634Arg alteration in exon 11 ([@B3]).

On the contrary, MEN2B, where MTC which is associated with pheochromocytoma and other additional clinical features (e.g., mucosal neuromas), is mostly associated with the Met918Thr variant in exon 16.

While genetic testing is mandatory whenever the familial form of MTC is suspected, germline *RET* testing may also be recommended in all patients with newly diagnosed C cell hyperplasia (CCH) or apparently sporadic MTC, since approximately 7% of patients, who would appear to have a "sporadic" form, in truth have an unsuspected germline variant in the *RET* proto-oncogene.

In the past decade, additional *RET* variants, unknown at the time of the International *RET* Consortium ([@B7]), have been discovered. These include very rare germline *RET* variants ([@B8]) often observed in a single affected member. However, the germline *RET* proto-oncogene variants identified during the past 20 years are localized in specific regions and involve eight exons (exons 5, 8, 10, 11, 13, 14, 15, 16) ([@B9]).

We here report the first two cases of MTC associated with the variant of exon 2 of *RET* proto-oncogene causing the substitution of Leucine with Methionine at codon 56 (p.L56M; rs145633958), which, to the best of our knowledge, has not previously been reported in association to MTC. In one case, the diagnosis of MEN2A cannot be excluded, considering the concomitant occurrence of pheochromocytoma.

Interestingly, the above-mentioned variant has been described in association with Hirschsprung disease, which has been excluded in these two patients.

Case presentation and description of laboratory investigations and diagnostic tests {#s2}
===================================================================================

Patient 1: A 62-year man came to our attention for an incidentally discovered right adrenal mass of 5 cm in diameter, detected during abdominal ultrasound evaluation for suspected nephrolithiasis. An abdominal computer tomography scan showed an adrenal mass suggestive of adrenal adenoma, without the typical radiological characteristics of pheochromocytoma.

The patient had hypertension which was well controlled by lercanidipine 10 mg/day. His family history was negative for endocrine disease.

Blood cortisol, aldosterone, adrenal androgens levels, and 24-h urinary catecholamine and metanephrines levels were normal. However, in consideration of the size of the tumor, the patient was referred for laparoscopic adrenalectomy. Surprisingly, final histology revealed a 55 mm pheochromocytoma. Because of the presence of bilateral thyroid micronodules (7 mm on right lobe and 9 mm on left lobe), serum calcitonin was measured, showing mildly elevated basal levels (20 pg/ml) and post i.v. calcium gluconate levels (296 and 366 pg/ml 2 and 3 min after the infusion, respectively). Fine needle aspiration biopsy (FNAB) performed on the left nodule confirmed the suspicion of MTC. The patient underwent total thyroidectomy and central neck dissection. Final pathology showed diffuse CCH and a 4 mm medullary microcarcinoma on the left nodule which previously had undergone FNAB, and no lymph node involvement.

Patient 2: A 58 years-old woman came to our attention for tachycardia. Laboratory evaluation showed mild hyperthyroidism and thyroid ultrasound revealed a multinodular goiter. Thyroid scintiscan confirmed the diagnosis of a toxic multinodular goiter, with a 2 cm hyperfunctioning left nodule. A FNAB evaluation performed on the most relevant non-hyperfunctioning nodule (15 mm on right lobe) showed was benign features (Thy 2). Serum calcitonin was borderline increased (13.2 pg/ml). Due to the symptoms of hyperthyroidism and dysphagia, the patient underwent total thyroidectomy and the final histology showed struma with CCH and medullary multifocal microcarcinoma (maximum diameter 6 mm on left lobe).

Molecular analysis of *RET*-protoncogene
----------------------------------------

After obtaining informed consent, DNA was isolated from peripheral blood by a manual method (Roche Diagnostics, Basel, Switzerland, <http://www.roche.com/index.htm>). Molecular analysis of the *RET* onco-gene was performed by sequencing of the coding region and exon-intron boundaries of the exons 2, 5, 8, 10, 11, 13--16, as routinely performed in our laboratory. Primers used and the respective annealing temperatures are reported in Table [1](#T1){ref-type="table"}. PCR products were sequenced using the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA, <http://www.appliedbiosystems.com/absite/us/en/home.html>) in an automated sequencer ABI Prism 3500 Genetic Analyzer (Applied Biosystems).

###### 

Primers used for *RET* amplification and sequencing.

  **Oligo name**   **Sequence (5′ 3′)**              **Annealing temperature**
  ---------------- --------------------------------- ---------------------------
  RET-2F           GCT TCC CCT GTT TCC TTT TC        
  RET-2R           AGT GTC AGC GGC TGT GAT AA        
  RET-5F           CGT GCA GCA TTC TAA GGT CTC       
  RET-5R           CAT GTG TGT AGG GTG CTG CT        
  RET-8F           TGC TCC TGG CAC TGT CTT           
  RET-8R           TGG GGA CCA ATC ACT GTA CTC       
  RET-1OF          GGA CAC TGC CCT GGA AAT A         
  RET-1OR          ACT CGC CTC CCA GCA ATT T         
  RET-11F          ATA CGC AGC CTG TAC CCA CT        
                                                     58
  RET-11R          AAA TGG GGG CAG AAC ACA           
  RET-13F          CCA TCC TGA CCT GGT ATG GT        
  RET-13R          AAA CAG GGC AGG AGC AGT AG        
  RET-14F          GTC CAC CCC CTT ACT CAT TG        
  RET-14R          GTG GTG AGC CAT AGC ATG G         
  RET-15F          CCC CCG GCC CAG GTC TC            
  RET-15R          GCT CCA CTA ATC TTC GGT ATC TTT   
  RET-16F          TCT CCT TTA CCC CTC CTT CC        
  RET-16R          CAG TGA GGG GGT CAT TGC           

*Sanger* sequencing revealed in both patients a missense variant on exon 2 (c.166C\>A, p.L56M). This change from cytosine to adenine causes a substitution of Leucine with Methionine at codon 56. Genetic testing was performed also in first degree relatives and the same variant was found in the son of Patient 1, who is being followed with periodic ultrasonography and calcitonin measurements. In order to assess the frequency of this variant within our patient population, we also screened 100 healthy controls (200 alleles) by high-resolution melting analysis; these additional samples were used since the p.L56M was never found within the previous 250 patients referred to our laboratory with the suspicion of MEN2 or MTC. All screened subjects were from Northern, Central and Southern Italy. This screening resulted mute for the above-mentioned variant, indicating a frequency of \<1%.

Discussion {#s3}
==========

The *RET* proto-oncogene, located on the long arm of chromosome 10 (10q11.2), was first identified in 1985 by transfection of NIH 3T3 cells with human lymphoma DNA ([@B10]). The protein encoded by *RET* is a cellular tyrosine kinase transmembrane receptor that is divided into three domains: an N-terminal extracellular domain with cadherin-like regions, a cysteine-rich transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity ([@B11]). The activation of *RET* stimulates multiple pathways promoting cell growth, proliferation, differentiation and survival ([@B4]).

Once the role of the mutated *RET* in the development of hereditary forms of MTC became clear, *RET* genetic screening was introduced into clinical practice ([@B8]), providing an important contribution in the diagnosis of MTC. In fact, before the introduction of the *RET* genetic screening test in clinical practice, the diagnosis of MTC was exclusively relying on FNAB and serum calcitonin measurements ([@B12]), which made the identification of making the identification of the familial forms quite challenging. Nowadays, genetic screening is aimed at the early identification of family members who carry the same mutation as the index case and to propose an early treatment considering of the degree of risk associated with the detected variant ([@B13]).

Furthermore, the evidence that germline *RET* variants are present in about 6--7% of "apparently sporadic" cases of MTC confirms the need to perform genetic screening in all patients with MTC ([@B8]). If a variant is found, the case is then reclassified as hereditary, and genetic screening of the first-degree relatives is strongly recommended ([@B9]). Following such recommendation, we performed genetic testing in our two patients following the diagnosis of "sporadic" MTC and, for the first time, a variant in exon 2 of RET was detected in association with MTC. Moreover, in Patient 1 the diagnosis of MEN2A cannot be ruled out, in consideration of the concomitant occurrence of MTC and pheochromocytoma.

As often reported for the "new" variants, the question is if the *RET* germline variant represents a driving force of MTC or if it is an incidental finding due to the increased use of screening ([@B14]). In literature, rare variants which cannot be considered to be "polymorphisms" and which have an uncertain role in the pathogenesis on MTC are described as variants of unknown significance (VUS) ([@B15]). In our case, the frequency of p.L56M variant in the general population is \<1%, and cannot be considered a polymorphisms. Recently, the ClinVar database identified this mutation in the MEN2A. The clinical significance as been defined as "benign/likely benign," because "it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease"[^1^](#fn0001){ref-type="fn"}. On the other hand, further studies are necessary to confirm the possible pathogenic role of this variant in MTC development: in fact, in clinical practice, genetic studies are often limited to exons 5, 8, 10, 11, 13, 14, 15, 16, where the majority of known *RET* pathogenic germline variant is localized. Whether the variant described by our group can be considered "pathogenic" in MTC or even in MEN2A is a hypothesis that needs to be confirmed. However, an interesting consideration is that this very same variant had previously been reported in association with Hirschsprung\'s disease, the congenital absence of ganglion cells in the submucosal and myenteric plexi of the gut. *RET* is the main gene implicated in this condition which, as mentioned earlier, represents a rare clinical feature of a MEN 2A clinical variant ([@B6]). Approximately 50% of familial cases of MTC and 7--35% of non-familial cases of MTC have loss-of-function germline RET variants ([@B16]). The concomitant occurrence of Hirschsprung\'s disease and MEN 2 is a relatively rare event, due to the presence of a "Janus" variant in the *RET* proto-oncogene: these variants can act both as a gain-of-function and a loss-of-function variant. To date, four missense exon 10 *RET* variants have been implicated in this association, most frequently in codon C620 (mostly C620R and occasionally C620S, and rarely C620W), but also in other areas (e.g., C609, C611, and C618) ([@B6]). Common variants in the *RET* promoter (rs10900296; rs10900297), at a SOX10 binding site in intron 1 (rs2435357), and in exon 2 (rs1800858; c.135G\>A;p.A45A) have also been associated with Hirschsprung\'s disease, suggesting that common as well as rare variants might influence the occurrence of Hirschsprung\'s disease ([@B17]). It is important to mention that the presence of Hirschsprung\'s disease in our two patients was excluded based on clinical evaluation. However, the association between MTC and exon 2 p.L56M variant, which in turn is also related with a disease involved in MEN 2 phenotype, underlines the possibility of a pathogenic role of p.L56M variant in MTC. These findings need further confirmatory results. Nevertheless, it is important to underline the importance to expand the genetic evaluation for *RET* germline variants in MTC or MEN2A patients also to exon 2, especially if genetic testing has excluded the presence of the more common variants located within other exons.
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